Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2487-2487
    Abstract: Lung cancer is the leading cause of cancer-related mortality worldwide. Comprehensive genetic studies revealed multiple subgroups of lung cancer of which each comprises a distinct mutational pattern. Moreover, it was shown that genetic alterations in genes encoding for kinases like EGFR and ALK induce constitutive kinase activity which in turn makes these kinases promising drug targets. However, as the correlation between genetic alterations and protein-expression/ -activity is strongly influenced by co- and post-transcriptional as well as post-translational regulation, we characterized a broad panel of lung cancer cell lines and primary patient-derived lung cancer tissues by quantitative proteomic techniques to identify diagnostic biomarkers and potential drug targets. To this end we established a work-flow to extract large amounts of proteins from formalin fixed paraffin embedded (FFPE) tissues by using the FASP method. Purified proteins were subsequently subjected to a Super-SILAC-based experimental set-up that allows for identification and quantification of thousands of proteins and their post-translational modifications by high-end mass spectrometry. In this study we quantitatively characterized the proteomes of 60 FFPE lung cancer specimens and 20 lung cancer cell lines including squamous cell carcinoma, adenocarcinoma and small cell carcinoma of the lung, and moreover squamous cell carcinoma metastases derived from head-neck tumors and adenocarcinoma metastases from colorectal cancer in the lung. Using the Super-SILAC-based mass spectrometric approach we were able to identify and quantify around 4000 proteins per sample. Unsupervised clustering- and principal component analyses revealed that the detected protein expression patterns show a strong correlation with the histological subtypes of lung cancer. Furthermore, also squamous cell cancer metastases could be distinguished from primary lung cancers with similar histological morphology using their protein expression profiles. Collectively, this study provides a large set of proteomic biomarkers that can be used in future to improve lung cancer diagnostics including the discrimination of metastases in the lung. In particular the differential diagnosis of squamous cell carcinoma/metastases in the lung which was so far difficult due to a lack of appropriate biomarkers will be improved by the biomarker panels presented here. Moreover, the expression patterns of kinases discovered in our study is of interest regarding potential novel lung cancer therapies as overexpression of kinases such as FGFR can contribute to the malignant phenotype of lung cancer cells. Citation Format: Hanibal Bohnenberger, Philipp Ströbel, Hannah Henric-Petri, Christof Lenz, Alexander Emmert, Felix Bremmer, Jasmin Strecker, Rainer Holland, Marc Hinterthaner, Jasmin Corso, Sebastian Wagner, Stefan Küffer, Martin Sebastian, Lothar Bergmann, Bernd Danner, Friedrich A. Schöndube, Henning Urlaub, Hubert Serve, Thomas Oellerich. Comprehensive quantitative proteomic profiling of lung cancers reveals novel biomarkers and potential drug targets. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2487. doi:10.1158/1538-7445.AM2014-2487
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 3018-3018
    Abstract: B cell antigen receptors (BCR) transduce signals and thereby control important cell fate decisions of the B-lineage including differentiation, proliferation and B cell survival. The intracellular signaling networks are complex and mainly regulated through reversible protein phosphorylation on tyrosine, serine or threonine residues. This process is highly controlled to ensure regular B cell function. However, dysregulation of BCR signaling can induce immunodeficiency, autoimmune disorders and malignant transformation. Recently, it was demonstrated that besides chronic lymphocytic leukemia and diffuse large B cell lymphomas of the activated B cell-type also subgroups of Burkitt lymphomas (BL) critically depend on BCR signaling that is enhanced due to TCF3 or ID3mutations. Thus, targeting of BCR signaling pathways by small molecule inhibitors is a promising therapeutic strategy for BCR-dependent BL. In order to identify putative novel drug targets, comprehensive knowledge about BCR effectors in BL cells is essential. We combined quantitative mass spectrometry (MS) and next generation sequencing (NGS) to globally characterize the dynamics of BCR-induced signaling and its impact on the (phospho)proteome and transcriptome of BL cells. We identified and quantified 8360 phosphorylation sites, of which 885 were regulated by BCRs in BL cells. Of these, about 85% have not been described before in the context of B- or lymphoma cells. Thus, the approach uncovered many unknown BCR effectors. The identified effector proteins belong to various functional groups, of which kinases, transcription factors and cytoskeleton regulators are most represented. Phosphoproteomic analyses revealed strong activatory phosphorylation patterns in several kinases. To complement and verify these data, we performed a kinobead-based kinase activity profiling in resting and activated BL cells. The combined data reveal the activation of known tyrosine kinases, but also of kinases with yet unknown function in BCR signaling. Particularly, certain MAP-kinases and other cell cycle regulators, such as kinases of the NEK family were highly activated in BL cells. Utilizing transcriptome sequencing, we furthermore identified about 150 genes that are differentially transcribed up to two hours after BCR stimulation. Correlating these data with expression proteomics, we investigated, how this genetic regulation affects protein expression in BL cells. Taken together, our large-scale study elucidates the molecular effects of BCR activation in BL in a comprehensive manner and reveals for the first time the dynamic interplay between receptor-triggered kinase activation, phosphorylation events and mRNA-/protein expression changes in these cells. Furthermore, the approach to combine proteomic, genetic and cell biological techniques also allowed us to decipher the influence of Myc overexpression on BCR signaling and provides data on possible molecular drug targets for the treatment of Burkitt’s lymphoma that have to be validated in further independent experiments. In case Myc was overexpressed Ca2+ signaling pathways were suppressed, while activity of other BCR-dependent pathways was enhanced. Manipulation of these altered activation patterns by certain small molecule inhibitors turned out to efficiently suppress BL cell growth. Disclosures: Schütz: Chronix Biomedical: Employment. Beck:Chronix Biomedical: Employment.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 3594-3594
    Abstract: Acute myeloid leukemia (AML) is a genetically heterogeneous disease where multiple driver mutations coincide in branching hematopoietic subclones leading to malignant transformation. One important class of mutations alters the function of signaling intermediates such as FLT3, thereby helping AML cells to overcome the physiological communication with their microenvironment. To investigate, if also non-mutated signaling molecules might be potential drug targets in AML, we performed an unbiased proteomic kinase activity profiling. Our (phospho)proteomic and functional analyses revealed spleen tyrosine kinase (SYK) and Bruton’s tyrosine kinase (BTK) as novel non-mutated drug targets in AML. By immunohistochemical analyses we identified expression of both kinases in more than 70% of analyzed AML cases. Oncogenic SYK signaling in AML cells turned out to be critically regulated by beta-integrins upon intercellular contact formation between AML cells and bone marrow stroma cells. BTK, however, turned out to act downstream of FLT3-ITD to activate MYC-dependent oncogenic transcriptional programs. FLT3-ITD expression induced activation of BTK in cell culture models and patient-derived AML cultures and sensitized them towards BTK inhibitors. This newly identified FLT3-ITD/BTK signaling axis can be therapeutically exploited by combining FLT3 and BTK inhibitors resulting in additive apoptosis-inducing effects. As in some cases also FLT3-ITD-negative AML cells showed response to BTK inhibition, we characterized the BTK interactome and its downstream signaling networks by quantitative proteomic techniques and identified the apoptosis sensor Toll-like receptor 9 (TLR9) as an upstream activator of BTK in FLT-ITD-negative cells. In the absence of FLT3-ITD, TLR9 activates BTK to induce cell survival through NFkB as revealed by transcriptome sequencing and cell biological studies. While TLR9 stimulation enhanced AML cell proliferation, knock-down of TLR9 induced a partial cell cycle arrest and apoptosis. Thus, we here describe a novel microenvironment-derived signaling axis that may represent an important mechanism of AML maintenance in various important clinical settings including efficient FLT3-ITD inhibition and cytotoxic therapy. Taken together, these data highlight the importance of interactions between AML cells and their microenvironment and unravel cooperative dependencies between mutant oncoproteins and wild-type kinases in AML pathogenesis. They also provide a rationale for the clinical evaluation of SYK- and BTK inhibitors in AML. Disclosures Beck: Chronic Biomedical: Employment. Schuetz:Chronix Biomedical: Employment.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2022
    In:  Sleep Vol. 45, No. Supplement_1 ( 2022-05-25), p. A171-A172
    In: Sleep, Oxford University Press (OUP), Vol. 45, No. Supplement_1 ( 2022-05-25), p. A171-A172
    Abstract: Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder. There are many conditions associated with OSA, including obesity hypoventilation syndrome, congestive heart failure, atrial fibrillation, pulmonary hypertension and pulmonary diseases. Majority of patients endorse daytime sleepiness, but family often report snoring and apneas. There are multiple screening tools, including the STOP-BANG. Scores 5 or above are high risk for OSA. Untreated OSA worsens comorbidities and increases risk of myocardial infarction and stroke. We provided physicians with this screening tool to help risk stratify, thus providing better patient education and treatment. Methods Physicians educated on OSA, STOP-BANG and documentation in didactic sessions. Patients ages 18 and older provided with questionnaire. Physicians measured neck circumference and BMI. Questionnaire reviewed with patient and education given. If high risk, sleep medicine referral recommended. Physicians documented in charts about discussion, risk category and referral status. Results Total of 407 patients completed the questionnaire, but 67 patients were excluded for no neck circumference. Remaining 340 patients stratified by STOP-BANG scores: 128 Low, 142 Intermediate, 70 High Risk. From High Risk category, 20 patients referred to Sleep Medicine. Only 18 charts from the 50 not referred explained why, which included patient declining, already on CPAP, referral already in, and because outpatient sleep study was ordered instead. Data stratified for age, gender, BMI and neck circumference. Age range from the 340 total was 19-87-years-old. From High Risk, 39 were male and 31 female. BMI range for total was 17-61, while High Risk was 22-61. Neck circumference range for total was 12-21 inches, while High Risk was 12.5-17.5 inches. Conclusion The goal was not only to provide a validated screening tool, but also provide better OSA education for physicians and patients. Results indicate many patients were intermediate or high risk. Majority of patients had multiple comorbidities, including obesity, hypertension and diabetes. This study highlights the prevalence of OSA in an inner-city primary care clinic and challenges involved in screening all at risk patients. Further investigations could include the effect of more education, continued screening and effect of lifestyle changes in this vulnerable population. Support (If Any)  
    Type of Medium: Online Resource
    ISSN: 0161-8105 , 1550-9109
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2022
    detail.hit.zdb_id: 2056761-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Elsevier BV ; 2015
    In:  Cellular Signalling Vol. 27, No. 1 ( 2015-01), p. 125-134
    In: Cellular Signalling, Elsevier BV, Vol. 27, No. 1 ( 2015-01), p. 125-134
    Type of Medium: Online Resource
    ISSN: 0898-6568
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2015
    detail.hit.zdb_id: 1496718-2
    SSG: 12
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, Vol. 113, No. 20 ( 2016-05-17), p. 5688-5693
    Abstract: Burkitt's lymphoma (BL) is a highly proliferative B-cell neoplasm and is treated with intensive chemotherapy that, because of its toxicity, is often not suitable for the elderly or for patients with endemic BL in developing countries. BL cell survival relies on signals transduced by B-cell antigen receptors (BCRs). However, tonic as well as activated BCR signaling networks and their relevance for targeted therapies in BL remain elusive. We have systematically characterized and compared tonic and activated BCR signaling in BL by quantitative phosphoproteomics to identify novel BCR effectors and potential drug targets. We identified and quantified ∼16,000 phospho-sites in BL cells. Among these sites, 909 were related to tonic BCR signaling, whereas 984 phospho-sites were regulated upon BCR engagement. The majority of the identified BCR signaling effectors have not been described in the context of B cells or lymphomas yet. Most of these newly identified BCR effectors are predicted to be involved in the regulation of kinases, transcription, and cytoskeleton dynamics. Although tonic and activated BCR signaling shared a considerable number of effector proteins, we identified distinct phosphorylation events in tonic BCR signaling. We investigated the functional relevance of some newly identified BCR effectors and show that ACTN4 and ARFGEF2, which have been described as regulators of membrane-trafficking and cytoskeleton-related processes, respectively, are crucial for BL cell survival. Thus, this study provides a comprehensive dataset for tonic and activated BCR signaling and identifies effector proteins that may be relevant for BL cell survival and thus may help to develop new BL treatments.
    Type of Medium: Online Resource
    ISSN: 0027-8424 , 1091-6490
    RVK:
    RVK:
    Language: English
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date: 2016
    detail.hit.zdb_id: 209104-5
    detail.hit.zdb_id: 1461794-8
    SSG: 11
    SSG: 12
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Cell, Elsevier BV, Vol. 31, No. 4 ( 2017-04), p. 549-562.e11
    Type of Medium: Online Resource
    ISSN: 1535-6108
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2017
    detail.hit.zdb_id: 2074034-7
    detail.hit.zdb_id: 2078448-X
    SSG: 12
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 1056-1056
    Abstract: Abstract 1056 B cell antigen receptors (BCR) transmit information via posttranslational protein modifications, most importantly protein phosphorylation. BCR signaling is a complex process that regulates differentiation and activation responses of the B-lineage. Dysregulation of BCR signaling can induce malignant transformation that can result in the onset of leukemia or lymphoma. To date our understanding of normal- versus malignant B cell biology points to differences in properties of BCR signaling that may be amenable to selective therapeutic targeting. However, comprehensive knowledge about BCR signaling pathways is still lacking which makes it difficult to understand the molecular events that drive B cell function and malignant transformation. To globally characterize BCR signaling, we have applied quantitative phosphoproteomic techniques that allowed us to identify and quantify about 10000 phosphorylation sites as a function of BCR stimulus, time, and subcellular location. Our phosphoproteome approach uncovered many novel BCR signaling effectors and their site-specific phosphorylation dynamics. The majority of phosphorylation events occured on serine/threonine residues, while only about one percent was detected at tyrosine residues. Interestingly, most of the identified proteins contain multiple phosphorylation sites showing different kinetics upon BCR stimulation, suggesting that they serve as signal integrators. Moreover, our functional analysis revealed that certain phosphorylation sites in adapter proteins are not only relevant for regulating the onset but also the termination of BCR signaling. Such signal termination is at least partly achieved by coupling the phosphotyrosine-dependent formation of BCR signalosomes to the kinetically flexible cytosolic Ca2+ concentration. In summary, our analysis revealed the complex composition of BCR signaling pathways and their regulation, and hence provides a basis for the identification of potential BCR-associated drug targets in the future. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Blood, American Society of Hematology, Vol. 125, No. 12 ( 2015-03-19), p. 1936-1947
    Abstract: Two novel transducer modules consisting of BTK in combination with either FLT3-ITD or TLR9 induce distinct oncogenic signaling programs. This study suggests subtype-specific treatment strategies, including BTK/FLT3 inhibitor combinations, and shows how TLR9 affects AML biology.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2015
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 15_Supplement ( 2015-08-01), p. 50-50
    Abstract: B cell antigen receptors (BCR) control important cell fate decisions of the B-lineage including differentiation, proliferation and B cell survival. Recently, it was demonstrated that beside chronic lymphocytic leukemia and diffuse large B cell lymphomas of the activated B cell-type also major subgroups of Burkitt lymphomas (BL) critically depend on BCR expression. As intensive chemotherapy and anti-CD20 antibodies are the current treatment strategies, pharmacological interference with critical BCR signaling pathways might open up the possibility for targeted therapies in BL. Such targeted therapeutic approaches are needed in particular for elderly patients and patients with endemic BL in developing countries. In order to (i) identify putative drug targets in BL and (ii) to elucidate BCR induced processes, we characterized BCR signaling in BL by quantitative phosphoproteomics and transcriptome sequencing. We identified about 10.000 phospho-sites in various BL cell-types, of which more than 1000 in almost 600 proteins were regulated in a BCR-dependent manner leading to dynamic transcription of more than 100 genes. The identified BCR signaling effectors belong to various functional groups, of which kinases, transcription factors and cytoskeleton regulators are most represented and bioinformatic analyses revealed that 83% of the identified BCR effectors were not described in the context of B cells or lymphoma before. For instance, we identified a cell surface receptor that is highly expressed in BL and whose expression is regulated by the transcription factor c-Myc which is known to be frequently dysregulated in BL. ShRNA mediated knockdown of the cell surface receptor in BL cells impaired phosphorylation of spleen tyrosine kinase (Syk) and B-cell linker protein (BLNK) upon BCR stimulation, most probably due to dysregulation of the cytoskeleton. By using stable isotope labeling with amino acids in cell culture (SILAC) we investigated in a comprehensive manner, how the newly identified BCR co-receptor influences BCR signaling. Our study is a considerable complement to recent genetic studies that elucidated the mutational landscape in BL as it reveals mechanisms of signaling addiction to non-mutated BCR effector proteins that have to be validated in the future. Citation Format: Carmen Doebele, Jasmin Corso, Anjali Cremer, Silvia Muench, Julia Beck, Christof Lenz, Hanibal Bohnenberger, Astrid Wachter, Tim Beissbarth, Ekkehard Schütz, Hubert Serve, Henning Urlaub, Thomas Oellerich. Elucidation of B cell receptor signaling in Burkitt's lymphoma reveals novel signaling nodes with potential therapeutic relevance. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 50. doi:10.1158/153 8-7445.AM2015-50
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages